Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
ViroMissile, Inc.
St. Jude Children's Research Hospital
MacroGenics
City of Hope Medical Center
University of Florida
Immatics US, Inc.
University of Southern California
University Health Network, Toronto
Memorial Sloan Kettering Cancer Center
HiFiBiO Therapeutics
Seattle Children's Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
HiFiBiO Therapeutics
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Valo Therapeutics Oy
Guangzhou FineImmune Biotechnology Co., LTD.
Iovance Biotherapeutics, Inc.
Eli Lilly and Company
Eli Lilly and Company
Centre Hospitalier Universitaire Vaudois
Y-mAbs Therapeutics
National Cancer Institute (NCI)
Xencor, Inc.
National Institutes of Health Clinical Center (CC)
Pfizer
DNAtrix, Inc.
National Cancer Institute (NCI)
BioEclipse Therapeutics
Adaptimmune
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
University of Pennsylvania
Pfizer
Prelude Therapeutics
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
MacroGenics
Pfizer
Seagen Inc.
Case Comprehensive Cancer Center
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Celgene
Memorial Sloan Kettering Cancer Center